LLY Lilly Eli & Co

All LLY filings Filing statistics SEC Website

Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines. We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes. In addition, as discussed below, for some products we have additional effective intellectual property protection in the form of data protection under pharmaceutical regulatory laws. The patent protection anticipated to be of most relevance to human pharmaceuticals is provided by national patents claiming the active ingredient (the compound patent), particularly those in major markets such as the

Company profile

Ticker

LLY

Exchange

NYSE

CEO

David A. Ricks

Incorporated in

Indiana

Location

Indiana

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals: Major

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries • Abbott Laboratories • Bristol Myers Squibb • AbbVie • Mylan • Celgene • Endo International ...

Former names

Lilly Eli & Co Et Al

SEC CIK

0000059478

Corporate docs

Articles of Incorporation & Bylaws

IRS number

350470950

LLY stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart LLY financial data

Download latest Excel data (2019 Q2) View latest Excel data (2019 Q2)

Quarter (USD)	Jun 19	Mar 19	Dec 18	Sep 18
Revenue	5.64B	5.09B	6.44B	6.06B
Net income	1.33B	4.24B	1.13B	1.15B
Diluted EPS	1.44	4.31	1.1	1.12
Net profit margin	23.55%	83.30%	17.47%	18.96%
Net change in cash	253.8M	-5.28B	-1.64B	2.14B
Cash on hand	2.29B	2.04B	7.32B	8.96B
Cost of revenue	1.12B	1.14B	1.59B	1.56B

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue	24.56B	22.87B	21.22B	19.96B
Net income	3.23B	-204.1M	2.74B	2.41B
Diluted EPS	3.13	-0.19	2.58	2.26
Net profit margin	13.16%	-0.89%	12.90%	12.07%
Net change in cash	784.5M	1.95B	915.7M	-205.2M
Cash on hand	7.32B	6.54B	4.58B	3.67B
Cost of revenue	6.43B	6.15B	5.71B	5.04B

Financial data from company earnings reports

Financial report summary

Management Discussion

Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2018, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: advertising, aforementioned, argument, Baqsimi, Centrexion, Colorado, Commonwealth, complied, conclusion, dialogue, discrete, false, immovable, impending, Kentucky, maintenance, matter, open, partnership, passed, published, rapidly, reasserting, reconsider, renewal, rulemaking, Saskatchewan, security, somatostatin, subpoena, Supplemental, Vermont, Weiler, withdrew

Removed: apply, Augusta, claim, cluster, delivery, device, entity, episodic, erosion, exit, fee, forecasted, Georgia, headache, Posilac, priority, production, rbst, recognition, sentence, site, Strattera, treated, unpredictable

From filing 10-Q 2019 Q2